Hangzhou Tigermed Consulting (SHE:300347) — Market Cap & Net Worth
Market Cap & Net Worth: Hangzhou Tigermed Consulting (300347)
Hangzhou Tigermed Consulting (SHE:300347) has a market capitalization of $4.25 Billion (CN¥29.04 Billion) as of June 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #4030 globally and #641 in its home market, demonstrating a 8.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou Tigermed Consulting's stock price CN¥39.36 by its total outstanding shares 737901250 (737.90 Million). Review 300347 total debt and obligations to assess the company's total debt and financial obligations.
Hangzhou Tigermed Consulting Market Cap History: 2015 to 2026
Hangzhou Tigermed Consulting's market capitalization history from 2015 to 2026. Data shows growth from $2.11 Billion to $4.25 Billion (5.62% CAGR).
Index Memberships
Hangzhou Tigermed Consulting is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.39 Trillion | 0.31% | #56 of 100 |
Weight: Hangzhou Tigermed Consulting's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hangzhou Tigermed Consulting Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou Tigermed Consulting's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.90x
Hangzhou Tigermed Consulting's market cap is 0.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.90x
Hangzhou Tigermed Consulting's market cap is 6.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.86 Billion | $1.17 Billion | $140.65 Million | 1.59x | 13.24x |
| 2017 | $2.43 Billion | $1.69 Billion | $301.01 Million | 1.44x | 8.08x |
| 2018 | $2.97 Billion | $2.30 Billion | $472.18 Million | 1.29x | 6.29x |
| 2019 | $6.61 Billion | $2.80 Billion | $841.63 Million | 2.36x | 7.85x |
| 2020 | $16.97 Billion | $3.19 Billion | $1.75 Billion | 5.32x | 9.70x |
| 2021 | $13.44 Billion | $5.21 Billion | $2.87 Billion | 2.58x | 4.68x |
| 2022 | $11.09 Billion | $7.09 Billion | $2.01 Billion | 1.56x | 5.53x |
| 2023 | $5.87 Billion | $7.38 Billion | $2.02 Billion | 0.79x | 2.90x |
| 2024 | $5.90 Billion | $6.60 Billion | $405.14 Million | 0.89x | 14.56x |
| 2025 | $6.12 Billion | $6.83 Billion | $887.89 Million | 0.90x | 6.90x |
Competitor Companies of 300347 by Market Capitalization
Companies near Hangzhou Tigermed Consulting in the global market cap rankings as of June 17, 2026.
Key companies related to Hangzhou Tigermed Consulting by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Hangzhou Tigermed Consulting Historical Marketcap From 2015 to 2026
Between 2015 and today, Hangzhou Tigermed Consulting's market cap moved from $2.11 Billion to $ 4.25 Billion, with a yearly change of 5.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.25 Billion | -30.58% |
| 2025 | CN¥6.12 Billion | +3.81% |
| 2024 | CN¥5.90 Billion | +0.54% |
| 2023 | CN¥5.87 Billion | -47.09% |
| 2022 | CN¥11.09 Billion | -17.50% |
| 2021 | CN¥13.44 Billion | -20.78% |
| 2020 | CN¥16.97 Billion | +156.79% |
| 2019 | CN¥6.61 Billion | +122.59% |
| 2018 | CN¥2.97 Billion | +21.97% |
| 2017 | CN¥2.43 Billion | +30.71% |
| 2016 | CN¥1.86 Billion | -11.84% |
| 2015 | CN¥2.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Hangzhou Tigermed Consulting was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.25 Billion USD |
| MoneyControl | $4.25 Billion USD |
| MarketWatch | $4.25 Billion USD |
| marketcap.company | $4.25 Billion USD |
| Reuters | $4.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more